[go: up one dir, main page]

DK1676847T3 - Polymorfe former af rifaximin som antibiotika - Google Patents

Polymorfe former af rifaximin som antibiotika

Info

Publication number
DK1676847T3
DK1676847T3 DK06004219T DK06004219T DK1676847T3 DK 1676847 T3 DK1676847 T3 DK 1676847T3 DK 06004219 T DK06004219 T DK 06004219T DK 06004219 T DK06004219 T DK 06004219T DK 1676847 T3 DK1676847 T3 DK 1676847T3
Authority
DK
Denmark
Prior art keywords
rifaximin
antibiotics
polymorphic forms
polymorphic
forms
Prior art date
Application number
DK06004219T
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1676847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK1676847T3 publication Critical patent/DK1676847T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK06004219T 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika DK1676847T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
DK1676847T3 true DK1676847T3 (da) 2009-05-11

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06004219T DK1676847T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum

Country Status (37)

Country Link
US (5) US7045620B2 (da)
EP (6) EP1676847B1 (da)
JP (5) JP2005139161A (da)
KR (4) KR20050043589A (da)
CN (4) CN1613858A (da)
AR (3) AR043547A1 (da)
AT (3) ATE421965T1 (da)
AU (2) AU2004200964A1 (da)
BR (2) BRPI0402382A (da)
CA (2) CA2460384A1 (da)
CL (1) CL2004000498A1 (da)
CO (1) CO5560083A1 (da)
CY (3) CY1108017T1 (da)
DE (4) DE602004019296D1 (da)
DK (3) DK1676847T3 (da)
ES (3) ES2320161T3 (da)
HR (2) HRP20040265A2 (da)
IL (2) IL160798A0 (da)
IT (1) ITMI20032144A1 (da)
JO (1) JO2470B1 (da)
MA (1) MA27069A1 (da)
MD (1) MD3653G8 (da)
ME (1) ME00424B (da)
MX (2) MXPA04002353A (da)
NO (1) NO334950B1 (da)
NZ (1) NZ531622A (da)
PL (3) PL1557421T3 (da)
PT (3) PT1557421E (da)
RS (4) RS54568B1 (da)
RU (1) RU2270200C2 (da)
SI (3) SI1676847T1 (da)
TN (2) TNSN04044A1 (da)
TW (1) TWI285107B (da)
UA (1) UA86384C2 (da)
WO (1) WO2005044823A2 (da)
YU (1) YU24804A (da)
ZA (1) ZA200401948B (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PT2054066E (pt) 2006-08-02 2015-07-16 Salix Pharmaceuticals Inc Métodos para tratamento de enterite por radiação
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EP2257557A4 (en) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
DK2252148T3 (da) 2008-02-26 2019-05-06 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af irritabel tarmsyndrom
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP3964066A1 (en) 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
KR20200100215A (ko) * 2009-10-27 2020-08-25 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
GEAP202112996A (en) * 2010-07-12 2021-09-10 Salix Pharmaceuticals Ltd Us Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
KR20140026379A (ko) 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
CA2908525C (en) 2013-04-12 2021-04-06 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
MX375805B (es) 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
US10842782B2 (en) 2016-03-24 2020-11-24 Sandoz Ag Storage stable composition comprising rifaximin alpha
ES2700423T3 (es) 2016-03-24 2019-02-15 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP3518924B1 (en) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
WO2018197538A1 (en) 2017-04-26 2018-11-01 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel
WO2020128583A1 (en) * 2018-12-19 2020-06-25 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4034091A1 (en) 2019-09-24 2022-08-03 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
JP2023531268A (ja) 2020-06-26 2023-07-21 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU1234002A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
EP2257557A4 (en) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
US8173801B2 (en) 2012-05-08
DE602004006367T2 (de) 2007-09-06
CN1613858A (zh) 2005-05-11
HK1092150A1 (en) 2007-02-02
EP1557421A1 (en) 2005-07-27
TW200515913A (en) 2005-05-16
RS54569B1 (sr) 2016-06-30
MXPA04002353A (es) 2005-05-11
PL1676847T3 (pl) 2009-07-31
CN101260114A (zh) 2008-09-10
CN101260115B (zh) 2011-11-23
ATE361927T1 (de) 2007-06-15
EP1676847B1 (en) 2009-01-28
CY1108017T1 (el) 2013-09-04
MXPA06002644A (es) 2006-06-06
WO2005044823A2 (en) 2005-05-19
KR20070113327A (ko) 2007-11-28
PT1676848E (pt) 2009-04-09
DE602004006367D1 (de) 2007-06-21
JP2007509904A (ja) 2007-04-19
UA86384C2 (uk) 2009-04-27
ITMI20032144A1 (it) 2005-05-08
JP2011057698A (ja) 2011-03-24
EP1682556A2 (en) 2006-07-26
US20120059023A1 (en) 2012-03-08
DE602004019298D1 (de) 2009-03-19
JP2011046738A (ja) 2011-03-10
CN1886408B (zh) 2010-06-09
MD3653F2 (en) 2008-07-31
US20050101598A1 (en) 2005-05-12
MD20060080A (en) 2006-11-30
KR20050043589A (ko) 2005-05-11
CN101260114B (zh) 2012-11-28
AU2004287601A1 (en) 2005-05-19
CY1108964T1 (el) 2014-07-02
TWI285107B (en) 2007-08-11
ATE421965T1 (de) 2009-02-15
DE602004006367C5 (de) 2019-04-04
ES2244364T1 (es) 2005-12-16
JP2005139161A (ja) 2005-06-02
US20110160449A1 (en) 2011-06-30
BRPI0407149A (pt) 2006-02-07
MD3653G8 (ro) 2016-08-31
DK1557421T3 (da) 2007-09-17
RS20060168A (sr) 2008-09-29
NZ531622A (en) 2004-10-29
AR043547A1 (es) 2005-08-03
CY1108909T1 (el) 2014-07-02
HK1092151A1 (en) 2007-02-02
DK1676848T3 (da) 2009-05-11
CA2538546C (en) 2011-04-19
EP1676847A1 (en) 2006-07-05
US20080132530A1 (en) 2008-06-05
HK1073657A1 (en) 2005-10-14
ME00424B (me) 2011-10-10
RS20150292A1 (sr) 2015-10-30
IL174271A0 (en) 2006-08-01
SI1676847T1 (sl) 2009-06-30
CA2538546A1 (en) 2005-05-19
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
AU2004287601B2 (en) 2009-02-26
KR100867751B1 (ko) 2008-11-10
ES2244364T3 (es) 2007-12-01
SI1676848T1 (sl) 2009-06-30
IL160798A0 (en) 2004-08-31
PT1557421E (pt) 2007-07-31
ES2320160T4 (es) 2011-03-09
MA27069A1 (fr) 2004-12-20
US8404704B2 (en) 2013-03-26
EP1676848B1 (en) 2009-01-28
RS20150291A1 (sr) 2015-10-30
SI1557421T1 (sl) 2007-08-31
AR081992A2 (es) 2012-10-31
YU24804A (sh) 2006-08-17
HRP20060093B1 (hr) 2015-12-18
PL1557421T3 (pl) 2007-08-31
US20050272754A1 (en) 2005-12-08
AU2004200964A1 (en) 2005-05-26
EP1676848A1 (en) 2006-07-05
AU2004287601B8 (en) 2009-03-05
JP5635376B2 (ja) 2014-12-03
NO20061110L (no) 2006-04-19
JP2014177500A (ja) 2014-09-25
ZA200401948B (en) 2004-04-29
RU2270200C2 (ru) 2006-02-20
CN1886408A (zh) 2006-12-27
DE602004019296D1 (de) 2009-03-19
TNSN06069A1 (en) 2007-10-03
BRPI0402382A (pt) 2005-06-28
CL2004000498A1 (es) 2005-03-11
RU2004108953A (ru) 2005-10-27
AR081991A2 (es) 2012-10-31
KR20070113326A (ko) 2007-11-28
TNSN04044A1 (en) 2006-06-01
RS54568B1 (sr) 2016-06-30
NO334950B1 (no) 2014-08-04
EP2210893A1 (en) 2010-07-28
IL174271A (en) 2010-12-30
CO5560083A1 (es) 2005-09-30
US7045620B2 (en) 2006-05-16
KR20060110737A (ko) 2006-10-25
DE04005541T1 (de) 2005-12-29
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
ATE421966T1 (de) 2009-02-15
KR100855084B1 (ko) 2008-08-29
EP1557421B1 (en) 2007-05-09
RS54571B1 (sr) 2016-06-30
KR100883216B1 (ko) 2009-02-13
US7915275B2 (en) 2011-03-29
CN101260115A (zh) 2008-09-10
HRP20060093A2 (en) 2006-05-31
BRPI0407149A8 (pt) 2019-01-15
PT1676847E (pt) 2009-04-09
JO2470B1 (en) 2009-01-20
CA2460384A1 (en) 2005-05-07
JP5199576B2 (ja) 2013-05-15
ES2320161T3 (es) 2009-05-19

Similar Documents

Publication Publication Date Title
DK1676848T3 (da) Polymorfe former af rifaximin som antibiotika
SE0302305D0 (sv) Novel Compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DE602004018602D1 (de) Mikrospiegel
ATE463248T1 (de) Cephem-verbindungen
IS8228A (is) Ný asetídínefnasambönd
FI20030030A0 (fi) Uusia yhdisteitä
IS8089A (is) Efnasambönd
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
IS8292A (is) Ný efnasambönd
NO20031736D0 (no) Forbindelser
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
SE0303452D0 (sv) New compounds
DE602004028552D1 (de) Nockenwellenversteller
EP1793812A4 (en) ANTIBIOTIC CONNECTION
EP1756034A4 (en) ANTIBIOTIC CONNECTION
SE0302667D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
FI20030095L (fi) Tasoituslana
SE0302369D0 (sv) New compounds
SE0302368D0 (sv) New compounds